Article Text

Download PDFPDF
Occult blood in faeces: a window into health beyond the colorectum?
  1. Uri Ladabaum1,2
  1. 1 Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA
  2. 2 Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
  1. Correspondence to Dr Uri Ladabaum, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 5187, USA; uri.ladabaum{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

After decades of research, testing for occult blood in faeces is firmly established as a method to screen for colorectal cancer (CRC). Such testing is based on the relatively simple premise that asymptomatic CRCs, and some CRC precursors, may lose small amounts of blood into faeces. The provocative study by Libby et al in Gut,1 which reports the associations between a positive guaiac faecal occult blood test (gFOBT) result and all-cause as well as non-CRC mortality in the National Health Service Tayside Board area of Scotland, suggests that occult blood in faeces may be telling us more than we might have thought. If the eye is the window to the soul, is a faecal test the window to general health?

The current study confirms and expands on the observations of Chen et al, who reported a gradient relationship between all-cause mortality and faecal haemoglobin (f-Hb) concentration in population-based screening programmes in Keelung and Tainan, Taiwan.2 Chen et al and Libby et al found associations between occult blood in faeces and CRC mortality, which is not surprising. However, in the study by Chen et al, with median follow-up of 3.5 years and longest follow-up of 8 years, the adjusted HRs for all-cause mortality ranged from 1.15 (95% CI 1.07 to 1.24) to 1.67 (95% CI 1.54 to 2.07) for persons with f-Hb concentrations of 20–49 and ≥450 ng Hb/mL, respectively (trend test p<0.0001), compared with the reference group of 1–19 ng Hb/mL (whose risk did not differ from that of persons with undetectable f-Hb). …

View Full Text


  • Contributors UL.

  • Competing interests UL is a consultant of Medtronic and Motus and an advisory board member of Universal Dx.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles